首页 >
法规速递
-
Document: Minutes of the COMP meeting 18-19 February 2025-2025/3/27
2025-03-28查看详情 > -
Document: Organisation chart: Advisory functions-2025/5/2
2025-05-06查看详情 > -
ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions-2025/6/16
2025-06-16查看详情 > -
Development of Cancer Drugs for Use in Novel Combination - Determining the Contribution of the Individual Drugs’ Effects-2025/7/17
2025-07-18查看详情 > -
Document: Agenda of the PRAC meeting 1-4 September 2025-2025/9/1
2025-09-02查看详情 > -
Page: Maximum residue limits (MRL)-2025/10/6
2025-10-08查看详情 > -
Document: European medicines regulatory network incident management plan for medicines for human use-2025/11/13
2025-11-14查看详情 > -
国家药监局关于同意吉林、海南省药监局开展优化药品补充申请审评审批程序改革试点的批复-2025/12/10
2025-12-11查看详情 > -
关于将ONC201胶囊纳入《儿童抗肿瘤药物研发鼓励试点计划（星光计划）》试点项目的公示-2026/1/22
2026-01-23查看详情 > -
Document: European Medicines Agency (EMA) stakeholder relations management framework-2026/2/26
2026-02-27查看详情 >
